Immune-Onc Therapeutics is a clinical-stage company that is revolutionizing cancer treatment through immunotherapy. They are focused on developing novel myeloid checkpoint inhibitors, which target immune suppressive pathways and have the potential to transform current treatment approaches for blood cancers and solid tumors. By harnessing the body's own immune system, immunotherapy has already changed the way cancer is treated, and Immune-Onc aims to further unlock its potential.

While T-cell checkpoint inhibitors have emerged as the standard-of-care for certain cancers, they have only been effective in a subset of patients. Immune-Onc aims to help more people with different types of cancer benefit from immunotherapy by building a portfolio of novel myeloid checkpoint inhibitors. Their team, which includes experienced industry professionals, collaborates with leading academic institutions and nonprofit cancer organizations to discover and develop new approaches to cancer treatment.

Their efforts are supported by dedicated investors who share their vision of transforming cancer care. Located in Palo Alto, CA, Immune-Onc Therapeutics is committed to making groundbreaking immunotherapies a reality for patients. Learn more about their pipeline, team, and ongoing research on their website